ConductScience.org, home

Paper33669809

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.

Ventura F and 6 others. Biomedicines, 2021. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva. Papers, record 33669809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33669809

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.
PubMed
Journal
Biomedicines
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.89
iCite
Revised in PubMed
2021-03-16
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ventura FFranceschttps://orcid.org/0000-0001-9673-9405
2Williams EEleanorhttps://orcid.org/0000-0002-1331-9518
3Ikeya MMakotohttps://orcid.org/0000-0002-3930-8032
4Bullock ANAlex Nhttps://orcid.org/0000-0001-6757-0436
5Ten Dijke PPeter
6Goumans MJMarie-Joséhttps://orcid.org/0000-0001-9344-6746
7Sanchez-Duffhues GGonzalo

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
BFU2017-82421-PMinisterio de Ciencia e InnovaciónPubMed
106169/ZZ14/ZWellcomePubMed
STOPFOP grant number 821600FOP Friends and Innovative Medicines Initiative 2 Joint UndertakingPubMed
22379AFM-TelethonPubMed
Grant Italia 2020FOP ItaliaPubMed
202038Fundacio la Marato de TV3PubMed
PHAEDRA-IMPACTNetherlands Cardiovascular Research Initiative the Dutch Heart FoundationPubMed

Source PubMed

Download CSV of grants

References171

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123412444Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy.Eur J Orthop Surg Traumatol2013https://conductscience.org/library/papers/23412444PubMed
226721400Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification.Proc Natl Acad Sci U S A2016https://conductscience.org/library/papers/26721400PubMed
327027798Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.J Bone Miner Res2016https://conductscience.org/library/papers/27027798PubMed
419243289TGF-beta uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells.Future Oncol2009https://conductscience.org/library/papers/19243289PubMed
58242742Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors.Cell1993https://conductscience.org/library/papers/8242742PubMed
622949078Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.Stem Cells2012https://conductscience.org/library/papers/22949078PubMed
720463014Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.J Biol Chem2010https://conductscience.org/library/papers/20463014PubMed
828754575Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.Bone2018https://conductscience.org/library/papers/28754575PubMed
926493492Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.Prostate2016https://conductscience.org/library/papers/26493492PubMed
1016753021Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP).J Bone Miner Res2006https://conductscience.org/library/papers/16753021PubMed
1126585533Pioneering government-sponsored drug repositioning collaborations: progress and learning.Nat Rev Drug Discov2015https://conductscience.org/library/papers/26585533PubMed
1232304852Recent advances in the molecular mechanism of thalidomide teratogenicity.Biomed Pharmacother2020https://conductscience.org/library/papers/32304852PubMed
1321460849Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.Nat Med2011https://conductscience.org/library/papers/21460849PubMed
1421102460Conversion of vascular endothelial cells into multipotent stem-like cells.Nat Med2010https://conductscience.org/library/papers/21102460PubMed
1529097342Variable signaling activity by FOP ACVR1 mutations.Bone2018https://conductscience.org/library/papers/29097342PubMed
1632515349Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop.Elife2020https://conductscience.org/library/papers/32515349PubMed
1724500035iPS cells: a game changer for future medicine.EMBO J2014https://conductscience.org/library/papers/24500035PubMed
1827530160
The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Stem Cell Res Ther2016https://conductscience.org/library/papers/27530160PubMed
1921791431The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor.Blood2011https://conductscience.org/library/papers/21791431PubMed
2024691995SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.Cancer Res2014https://conductscience.org/library/papers/24691995PubMed

See all 171 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
41017808A Narrative Review of Phase II and III Clinical Trials for the Pharmacological Treatment of Fibrodysplasia Ossificans Progressiva (FOP): Efficacy, Safety, and Challenges in Treatment Strategies.Drug Des Devel Ther2025https://conductscience.org/library/papers/41017808PubMed
40416557
Combined rapamycin and mesenchymal stem/stromal cells derived from induced pluripotent stem cells-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
JBMR Plus2025https://conductscience.org/library/papers/40416557PubMed
40274382Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva.J Zhejiang Univ Sci B2025https://conductscience.org/library/papers/40274382PubMed
40121219Interplay between ALK2R206H mutant receptor and autophagy signaling regulates receptor stability and its chondrogenic functions.Cell Death Discov2025https://conductscience.org/library/papers/40121219PubMed
38500216iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.Stem Cell Res Ther2024https://conductscience.org/library/papers/38500216PubMed
38254701How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.Biomolecules2024https://conductscience.org/library/papers/38254701PubMed
38136984Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers.Genes (Basel)2023https://conductscience.org/library/papers/38136984PubMed
37521595Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions.Cureus2023https://conductscience.org/library/papers/37521595PubMed
36522666The role of miRNA and lncRNA in heterotopic ossification pathogenesis.Stem Cell Res Ther2022https://conductscience.org/library/papers/36522666PubMed
35637634Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.J Bone Miner Res2022https://conductscience.org/library/papers/35637634PubMed
35052819Editorial of Special Issue "Fibrodysplasia Ossificans Progressiva: Studies on Disease Mechanism towards Novel Therapeutic Approaches".Biomedicines2022https://conductscience.org/library/papers/35052819PubMed
34440363Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis.Genes (Basel)2021https://conductscience.org/library/papers/34440363PubMed

Download CSV of cited by

Genes46

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
ACVR190PubTator's text mininghttps://conductscience.org/library/genes/90NCBI Gene
ACVR1B91PubTator's text mininghttps://conductscience.org/library/genes/91NCBI Gene
ACVR2A92PubTator's text mininghttps://conductscience.org/library/genes/92NCBI Gene
ACVR2B93PubTator's text mininghttps://conductscience.org/library/genes/93NCBI Gene
ACVRL194PubTator's text mininghttps://conductscience.org/library/genes/94NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BMP1649PubTator's text mininghttps://conductscience.org/library/genes/649NCBI Gene
BMP4652PubTator's text mininghttps://conductscience.org/library/genes/652NCBI Gene
BMPR1A657PubTator's text mininghttps://conductscience.org/library/genes/657NCBI Gene
BMPR1B658PubTator's text mininghttps://conductscience.org/library/genes/658NCBI Gene
BMPR2659PubTator's text mininghttps://conductscience.org/library/genes/659NCBI Gene
ENPP25168PubTator's text mininghttps://conductscience.org/library/genes/5168NCBI Gene
FKBP1AP42285PubTator's text mininghttps://conductscience.org/library/genes/2285NCBI Gene
HIF1A3091PubTator's text mininghttps://conductscience.org/library/genes/3091NCBI Gene
ID23398PubTator's text mininghttps://conductscience.org/library/genes/3398NCBI Gene
ID33399PubTator's text mininghttps://conductscience.org/library/genes/3399NCBI Gene
INHBE83729PubTator's text mininghttps://conductscience.org/library/genes/83729NCBI Gene
JUNB3726PubTator's text mininghttps://conductscience.org/library/genes/3726NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene

See all 46 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33669809

GET https://conductscience.org/api/papers/v1/33669809/references?page=2